Cargando…

Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study

BACKGROUND: Real-world data on long-term outcomes of vedolizumab (VDZ) are scarce. OBJECTIVE: To assess long-term outcomes (up to 3 years) of VDZ in treating inflammatory bowel disease (IBD). DESIGN: A nationwide, prospective multicentre extension of a Swedish observational study on VDZ assessing Ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Visuri, Isabella, Eriksson, Carl, Karlqvist, Sara, Lykiardopoulos, Byron, Karlén, Per, Grip, Olof, Söderman, Charlotte, Almer, Sven, Hertervig, Erik, Marsal, Jan, Malmgren, Carolina, Delin, Jenny, Strid, Hans, Sjöberg, Mats, Bergemalm, Daniel, Hjortswang, Henrik, Halfvarson, Jonas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236258/ https://www.ncbi.nlm.nih.gov/pubmed/37274297 http://dx.doi.org/10.1177/17562848231174953

Ejemplares similares

Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study
por: Eriksson, Carl, et al.
Publicado: (2021)

Ustekinumab treatment in ulcerative colitis: Real‐world data from the Swedish inflammatory bowel disease quality register
por: Thunberg, Joel, et al.
Publicado: (2022)

The Risk of Serious Infections Before and After Anti-TNF Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study
por: Holmgren, Johanna, et al.
Publicado: (2022)

Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
por: Bergqvist, Viktoria, et al.
Publicado: (2017)

Differences in Whole-Blood Transcriptional Profiles in Inflammatory Bowel Disease Patients Responding to Vedolizumab Compared with Non-Responders †
por: Haglund, Sofie, et al.
Publicado: (2023)

Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease
por: Eriksson, Carl, et al.
Publicado: (2023)

Drug survival of anti‐TNF agents compared with vedolizumab as a second‐line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers
por: Rundquist, Sara, et al.
Publicado: (2020)

Downregulated Mucosal Autophagy, Alpha Kinase-1 and IL-17 Signaling Pathways in Active and Quiescent Ulcerative Colitis
por: Moraes Holst, Luiza, et al.
Publicado: (2022)

Prognostic Biosignatures at Ileocecal Resection: Hope or Reality?
por: Salomon, Benita, et al.
Publicado: (2021)

Inflammatory bowel disease registries for collection of patient iron parameters in Europe
por: Halfvarson, Jonas, et al.
Publicado: (2018)

Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
por: Bergqvist, Viktoria, et al.
Publicado: (2018)

Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease
por: Fleisher, Mark, et al.
Publicado: (2018)

Systemic Chemokine Levels with “Gut-Specific” Vedolizumab in Patients with Inflammatory Bowel Disease—A Pilot Study
por: Zwicker, Stephanie, et al.
Publicado: (2017)

Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay
por: Vande Casteele, Niels, et al.
Publicado: (2023)

Seasonal variations of urate in a Swedish adult population
por: Åkerblom, Axel, et al.
Publicado: (2017)

Real‐world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease
por: Bergqvist, Viktoria, et al.
Publicado: (2022)

Elevated fecal peptidase D at onset of colitis in Galphai2(-/-) mice, a mouse model of IBD
por: Bergemalm, Daniel, et al.
Publicado: (2017)

Gene Expression-Genotype Analysis Implicates GSDMA, GSDMB, and LRRC3C as Contributors to Inflammatory Bowel Disease Susceptibility
por: Söderman, Jan, et al.
Publicado: (2015)

Genetic variation and expression levels of tight junction genes identifies association between MAGI3 and inflammatory bowel disease
por: Norén, Elisabeth, et al.
Publicado: (2017)

Inverse and Concordant Mucosal Pathway Gene Expressions in Inflamed and Non-Inflamed Ulcerative Colitis Patients: Potential Relevance to Aetiology and Pathogenesis
por: Söderman, Jan, et al.
Publicado: (2022)

Changes in alcohol consumption after treatment for depression: a secondary analysis of the Swedish randomised controlled study REGASSA
por: Strid, Catharina, et al.
Publicado: (2019)

Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms
por: Lykiardopoulos, Byron, et al.
Publicado: (2016)

Ustekinumab Is Associated with Real-World Long-Term Effectiveness and Improved Health-Related Quality of Life in Crohn's Disease
por: Forss, Anders, et al.
Publicado: (2022)

Detailed Transcriptional Landscape of Peripheral Blood Points to Increased Neutrophil Activation in Treatment-Naïve Inflammatory Bowel Disease
por: Juzenas, Simonas, et al.
Publicado: (2022)

Gene Expression and Thiopurine Metabolite Profiling in Inflammatory Bowel Disease – Novel Clues to Drug Targets and Disease Mechanisms?
por: Haglund, Sofie, et al.
Publicado: (2013)

Combination treatment with 6-mercaptopurine and allopurinol in HepG2 and HEK293 cells – Effects on gene expression levels and thiopurine metabolism
por: Haglund, Sofie, et al.
Publicado: (2017)

Use of complementary and alternative medicine in Swedish patients with inflammatory bowel disease: a controlled study
por: Oxelmark, Lena, et al.
Publicado: (2016)

Vedolizumab-Associated Hypereosinophilia and Hepatoxicity
por: De Marco, Davide, et al.
Publicado: (2022)

Genetic Variation and Gene Expression Levels of Tight Junction Genes Indicates Relationships Between PTEN as well as MAGI1 and Microscopic Colitis
por: Norén, Elisabeth, et al.
Publicado: (2017)

Diagnostic value of fecal calprotectin in primary care patients with gastrointestinal symptoms: A retrospective Swedish cohort study
por: Rendek, Zlatica, et al.
Publicado: (2023)

Subphenotypes of inflammatory bowel disease are characterized by specific serum protein profiles
por: Andersson, Erik, et al.
Publicado: (2017)

Vedolizumab in the treatment of Crohn’s disease of the pouch
por: Khan, Freeha, et al.
Publicado: (2018)

Vedolizumab for chronic antibiotic-refractory pouchitis
por: Singh, Amandeep, et al.
Publicado: (2019)

The Early Experience With Vedolizumab in the United States
por: Kochar, Bharati, et al.
Publicado: (2019)

Combination of vedolizumab and immunomodulators in ulcerative colitis
por: Pinton, P
Publicado: (2021)

Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease
por: Vaughn, Byron P., et al.
Publicado: (2020)

Immigrants with dementia in Swedish residential care: an exploratory study of the experiences of their family members and Nursing staff
por: Rosendahl, Sirpa Pietilä, et al.
Publicado: (2016)

Swedish Universities Scales of Personality: Relation to Other Personality Instruments
por: Fagerberg, Tomas, et al.
Publicado: (2021)

Chronic Cholestatic Liver Injury Attributable to Vedolizumab
por: Stine, Jonathan G., et al.
Publicado: (2016)

A Case of Evan's Syndrome Induced by Vedolizumab
por: Jen, Henry, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5g4kog1qpqn1lalolh8qq0e9oq